Authors : Nsolo.T.Neema; Subba .Dil

Volume/Issue : Volume 9 - 2024, Issue 6 - June

Google Scholar : https://tinyurl.com/sypwsca7

Scribd : https://tinyurl.com/4j24fzmw

DOI : https://doi.org/10.38124/ijisrt/IJISRT24JUN222

Abstract : Sickle cell anaemia, a hereditary blood disorder characterized by abnormal haemoglobin, poses significant challenges globally, particularly in resource- limited settings. Despite advances in treatment, access to care and resources remains a persistent issue. This study aims to comprehensively understand the healthcare utilisation events experienced by sickle cell anaemic patients undergoing palliative therapy. This study aimed to assess and evaluate healthcare utilization events related to palliative therapy and satisfaction in sickle cell anaemic patients. The specific objectives were to identify healthcare utilization events which was patient satisfaction and to examine factors influencing these events, including demographic characteristics, disease severity, and access to healthcare services. In this study, a cross-sectional design was utilized to investigate healthcare utilization events and factors influencing these events among individuals with sickle cell anaemia receiving palliative therapy who were selectively chosen through simple random sampling, ensuring a representative selection from the target population. Data analysis was conducted using SPSS version 25.0 software, expressing continuous variables as means and categorical variables as frequencies and percentages. The descriptive analysis of 209 participants highlighted a predominance of females (60.3%) over males (39.7%), with the majority falling in the 18-27 age group (94.3%) and holding a Bachelor's degree (77.5%). Unemployment was prevalent (72.7%), and most participants reported satisfaction with sickle cell treatment (91.4%). In both univariate and multivariate analyses, gender, educational level, employment status, disease severity, and access to healthcare emerged as significant factors affecting patient satisfaction. These findings ultimately emphasize the complex interplay of demographic, socioeconomic, and healthcare access factors towards shaping patient satisfaction with sickle cell treatment modalities.

Keywords : Sickle Cell Anaemia, Healthcare Utilization Events, Healthcare Access, Palliative Therapy, Patient Satisfaction, Disease Severity, Demographic Characteristics.

References :

1. 1. 1. Ballas, S. K. (2002). Sickle Cell Anaemia: Progress in Pathogenesis and Treatment. Drugs, 62(8), 1143–1172.
2. Benjamin, L. (2008). Pain Management in Sickle Cell Disease: Palliative Care Begins at Birth?
3. Hematology, 2008(1), 466–474.
4. Carden, M. A., & Little, J. (2019). Emerging disease-modifying therapies for sickle cell disease.
5. Haematologica, 104(9), 1710–1719.
6. Ddungu, H. (2011). Palliative care: What approaches are suitable in developing countries? British Journal of Haematology, 154(6), 728–735.
7. Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H. (2016). CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 539(7629), 384–389.
8. Eaton, M. L., Have, J. S., Armstrong, F. D., Pegelow, C. H., & Thomas, M. (1995). Hospitalizations for Painful Episodes: Association with School Absenteeism and Academic Performance in Children and Adolescents with Sickle Cell Anemia. Issues in Comprehensive Pediatric Nursing, 18(1), 1–9.
9. Faculty of Medicine and Surgery, Helwan University, Egypt, & Eskandar, K. (2023). Breaking the Cycle: Innovative Approaches to Managing Sickle Cell Anemia. Journal of Clinical Research and Case Studies, 1–7.
10. Fiscella, K., Franks, P., Gold, M. R., & Clancy, C. M. (2000). Inequality in Quality: Addressing Socioeconomic, Racial, and Ethnic Disparities in Health Care. JAMA, 283(19), 2579–2584.
11. Garg, H., Tatiossian, K. J., Peppel, K., Kato, G. J., & Herzog, E. (2022). Gene Therapy as the New Frontier for Sickle Cell Disease. Current Medicinal Chemistry, 29(3), 453–466.
12. GBD 2021 Sickle Cell Disease Collaborators. (2023). Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: A systematic analysis from the Global Burden of Disease Study 2021. The Lancet. Haematology, 10(8), e585–e599.
13. Givens, M., Rutherford, C., Joshi, G., & Delaney, K. (2007). Impact of an Emergency Department Pain Management Protocol on the Pattern of Visits by Patients with Sickle Cell Disease. The Journal of Emergency Medicine, 32(3), 239–243.
14. Grosse, S. D., Schechter, M. S., Kulkarni, R., Lloyd-Puryear, M. A., Strickland, B., & Trevathan, E. (2009). Models of Comprehensive Multidisciplinary Care for Individuals in the United States With Genetic Disorders. Pediatrics, 123(1), 407–412.
15. Hassell, K. L. (2010). Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine, 38(4 Suppl), S512-521.
16. Hawley, P. (2017). Barriers to Access to Palliative Care. Palliative Care: Research and Treatment, 10, 1178224216688887.
17. Hemker, B. G., Brousseau, D. C., Yan, K., Hoffmann, R. G., & Panepinto, J. A. (2011). When children with sickle-cell disease become adults: Lack of outpatient care leads to increased use of the emergency department. American Journal of Hematology, 86(10), 863–865.
18. Iannone, R., Ohene-Frempong, K., Fuchs, E. J., Casella, J. F., & Chen, A. R. (2005). Bone marrow transplantation for sickle cell anemia: Progress and prospects. Pediatric Blood & Cancer, 44(5), 436– 440.
19. Johnston, E., Adesina, O., Amato, H., Paulukonis, S., & Bhatia, S. (2019). Acute Care Utilization at End-of-Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach to Sickle Cell Disease (S835). Journal of Pain and Symptom Management, 57(2), 500–501.
20. Kohne, E. (2011). Hemoglobinopathies. Deutsches Ärzteblatt International.
21. Lonergan, G. J., Cline, D. B., & Abbondanzo, S. L. (2001). Sickle Cell Anemia. RadioGraphics, 21(4), 971–994.
22. Meilianti, S., John, C., Duggan, C., O’campo, L., & Bates, I. (2023). How can pharmacists contribute to anaemia management? A review of literature and exploratory study on pharmacists’ role in anaemia. Exploratory Research in Clinical and Social Pharmacy, 9, 100231.
23. Namazzi, R., Bond, C., Conroy, A., Datta, D., Tagoola, A., Goings, M. J., Jang, J. H., Ware, R. E., Opoka, R. O., & John, C. C. (2024). Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood Journal, blood.2023021575.
24. Nwogu-Onyemkpa, E., Dongarwar, D., Salihu, H. M., Akpati, L., Marroquin, M., Abadom, M., & Naik, A. D. (2022). Inpatient palliative care use by patients with sickle cell disease: A retrospective cross-sectional study. BMJ Open, 12(8), e057361.
25. Osunkwo, I., Andemariam, B., Minniti, C. P., Inusa, B. P. D., El Rassi, F., Francis-Gibson, B., Nero, A., Trimnell, C., Abboud, M. R., Arlet, J.-B., Colombatti, R., de Montalembert, M., Jain, S., Jastaniah, W., Nur, E., Pita, M., DeBonnett, L., Ramscar, N., Bailey, T., … James, J. (2021). Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). American Journal of Hematology, 96(4), 404–417.
26. Panepinto, J. A., Brousseau, D. C., Hillery, C. A., & Scott, J. P. (2005). Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatric Blood & Cancer, 44(2), 182–186.
27. Pauling, L., Itano, H. A., Singer, S. J., & Wells, I. C. (1949). Sickle Cell Anemia, a Molecular Disease. Science, 110(2865), 543–548.
28. Power-Hays, A., & Ware, R. E. (2020). Effective use of hydroxyurea for sickle cell anemia in low- resource countries. Current Opinion in Hematology, 27(3), 172–180.
29. Signorelli, A. A. F., Ribeiro, S. B. F., Moraes-Souza, H., Oliveira, L. F. D., Ribeiro, J. B., Silva, S. H. D., Oliveira, D. F. F. D., & Ribeiro, M. F. F. (2013). Pain measurement as part of primary healthcare of adult patients with sickle cell disease. Revista Brasileira de Hematologia e Hemoterapia, 35(4).
30. Treadwell, M., Telfair, J., Gibson, R. W., Johnson, S., & Osunkwo, I. (2011). Transition from pediatric to adult care in sickle cell disease: Establishing evidence‐based practice and directions for research. American Journal of Hematology, 86(1), 116–120.
31. Tubman, V. N., Mohandas, N., & Abrams, C. S. (2023). New ASH initiatives to improve patient care of the long-overlooked Sickle Cell Disese. Blood Journal, blood.2023020145.